IsalaIsala kliniekenklinieken
Harry SuryapranataISALA Klinieken
Hosp. De WeezenlandenZwolle, The Netherlands
Harry SuryapranataHarry SuryapranataISALA KliniekenISALA Klinieken
HospHosp. De . De WeezenlandenWeezenlandenZwolle, The Zwolle, The NetherlandsNetherlands
AMI Interventionin DES Era and Beyond
AMI Interventionin DES Era and Beyond
AngioplastyAngioplasty SummitSummit: April 26, 2007: April 26, 2007
IsalaIsala kliniekenklinieken
ReperfusionReperfusion TherapyTherapy forfor STEMISTEMI
PCI has never been shown to reduce mortality, except in subsets PCI has never been shown to reduce mortality, except in subsets of pts with AMIof pts with AMI
AMI AMI MortalityMortality in in NetherlandsNetherlands
0
5
10
15
20
25
1950-1960 1960-1970 1980-1990 1990-2000PrePre--CCUCCU CCUCCU
ThrombolysisThrombolysisPrimaryPrimary
PCIPCI
%
ReperfusionReperfusionEraEra
30-Day Mortality
CAPTIM(n=840)
USIC(n=614)
PREMIR(n=1449)
0
2
4
6
8
3.8
4.8
3.3
6.7
5.5
4.4
ThrombolysisThrombolysisPrimaryPrimary PCIPCI 7.9
5.3
PrePre--hospitalhospital ThrombolysisThrombolysis
PCAT(n=6763)
%
IsalaIsala kliniekenklinieken
PrimaryPrimary PCI PCI vsvs ThrombolysisThrombolysis forfor STEMISTEMI
Boersma et al. EHJ 2006ZijlstraZijlstra et al. et al. EurEur HeartHeart J 2002J 2002
Mortality at 30 daysMortality at 30 daysPooled Analysis: PCI vs Lytics
0
3
6
9
12
EarlyEarly (<2h)(<2h) MediumMedium (2(2--4h)4h) LateLate (>4h)(>4h)
PCIPCILyticsLytics
5.05.03.93.9
6.36.3
4.14.1
12.112.1
4.74.7
%%
TimeTime--delay & 30delay & 30--d Mortalityd Mortality
ThrombolysisThrombolysis
PrimaryPrimary PCIPCI3
5
7
9
11
13
15
00--11 11--22 33--66 66--12h12h22--33
%%
PCAT Meta-Analysis (n=6763)
Are time-delays to P-PCI really NOT that important?
IsalaIsala kliniekenklinieken
Zwolle Zwolle RandomizedRandomized TrialTrialSymptomSymptom--toto--BalloonBalloon andand OneOne--yearyear MortalityMortality (%)(%)
De Luca et al. JACC 2003De Luca et al. JACC 2003
Every minute delay does count: not only for Every minute delay does count: not only for LyticsLytics, but also for P, but also for P--PCIPCI
0
3
6
9
12
15
4.4 4.7
8.59.7
1.5 1.2 0.80
5.76.3
1213
P = 0.02
P = NSP = NS
P = 0.006
AllAll PatientsPatients LowLow--RiskRisk HighHigh--RiskRisk(n=545)(n=545)(n=1791)(n=1791) (n=1246)(n=1246)
<< 2 h2 h 22--4 h4 h > 6 h> 6 h44--6 h6 h
7.5% increased risk of death for each 30-min delay
Y = 2.86 (Y = 2.86 (++ 1.46) + 0.0045X1.46) + 0.0045X11 + 0.000043X+ 0.000043X22
IschemicIschemic Time Time (min)(min)360360300300240240180180120120606000
1212
1010
88
66
44
22
00p < 0.001p < 0.001
RR death increased by7.5% for each 30-min
Adjusted RR [95% CI]:Adjusted RR [95% CI]:1.0751.075 [1.01[1.01--1.16]1.16]
De Luca, Suryapranata Circulation 2004De Luca, Suryapranata Circulation 2004
IsalaIsala kliniekenklinieken
Zwolle Zwolle PrePre--hospitalhospital TriageTriage in Transferring in Transferring patientspatients forfor PCIPCI
Symptom-Ambulance 91 min
Ambulance-Admission 49 min
Door-Balloon 38 min
TotalTotal178178’’
ZwolleZwolle PHIATPHIAT protocolprotocol (1998 (1998 -- ))PPrere--HHospitalospital IInfarctnfarct AAngioplastyngioplasty TTriageriage
35 Ambulances + computer35 Ambulances + computer--assisted assisted 1212--lead lead teletele--ECG, using algorithmECG, using algorithm
Identification of a large AMIIdentification of a large AMIAmbulance nurse only, no physicianAmbulance nurse only, no physician
Immediate transfer to Immediate transfer to CathlabCathlabRather than to nearest Hosp/CCU/ERRather than to nearest Hosp/CCU/ER
PCI Centre ZwolleReferral CenterAmbulance Transport
ZwolleZwolle
1.400.000
Amsterdam
Distance Range: 2 - 95 km
IsalaIsala kliniekenklinieken
Primary PCI for STEMI: Primary PCI for STEMI: Zwolle ExperienceZwolle Experience (1994(1994--2004)2004)
0
1
2
3
4
5
6
7
1994 1996 1998 2000 2002 2004
In-Hospital Mortality (%)
0
5
10
15
20
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Patients > 75 yrs (%)
0
2
4
6
8
10
12
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Hospital Stay (day)
-0,1
0,1
0,3
0,5
0,7
0,9
1,1
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Door-to-Balloon Time (hrs)
0
100
200
300
400
500
600
700
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Admitted STEMI(n=4732)
0
20
40
60
80
100
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
P C I C A B G C o ns e rv at iv e
Primary PCI
No Lytics used
IsalaIsala kliniekenklinieken
Routine Routine StentStent vsvs Balloon in a consecutive series of unselected ptsBalloon in a consecutive series of unselected ptsZwolleZwolle--6 6 ““RealReal WorldWorld”” RandomizedRandomized TrialTrial
StentStent BalloonBalloonPostPost--PCI PCI ResultsResults (n=849)(n=849) (n=834)(n=834)
TIMITIMI--3 Post3 Post (%)(%) 8888 8888MBG IIMBG II--IIIIII (%)(%) 8181 8080Distal Distal emboliemboli (%)(%) 1414 1818ComplCompl STST--resres (%)(%) 5656 5454LVEFLVEF (%)(%) 4444 4545LDH Q48hLDH Q48h (U/L)(U/L) 12271227 12861286
0
10
20
30
DeathDeath ReRe--MIMI Death/Death/ReRe--MIMI
TVRTVR MACEMACE
7.17.16.66.68.48.4
6.86.8
141412.412.4
19.619.6
20.720.7
26.326.326.326.626.626.6
%%OneOne--year Clinical Outcomeyear Clinical Outcome
Balloon (n=834)Balloon (n=834)Stent (n=849)Stent (n=849)
Suryapranata et al. Heart 2005Suryapranata et al. Heart 2005
• StentStent doesndoesn’’t improve t improve epiepi--/myo/myo--cardialcardial reperfusion, unlike to reduce mortalityreperfusion, unlike to reduce mortality• StentStent has never been shown to reduce mortality, as compared to balloohas never been shown to reduce mortality, as compared to balloonn
IsalaIsala kliniekenklinieken
STUDYSTENTING
n/N (%)BALLOON
n/N (%) OR (fixed) 95% CI Weight % OR 95% CI
CADILLAC 28/524 (5.3%) 16/528 (3.0%) 9.23 1.81 [0.97, 3.38] 0.061
CADILLAC 17/512 (3.3%) 28/518 (5.4%) 16.47 0.60 [0.32, 1.11] 1.0FRESCO 1/75 (1.3%) 4/75 (5.3%) 2.42 0.24 [0.03, 2.20] 0.36Jacksch et al 5/231 (2.2%) 7/231 (3.0%) 4.19 0.71 [0.22, 2.26] 0.56PAMI 26/452 (5.8%) 14/448 (3.1%) 8.11 1.89 [0.97, 3.67] 0.056PASTA 3/67 (4.5%) 6/69 (8.7%) 3.46 0.49 [0.12, 2.05] 0.49PSAAMI 4/44 (9.1%) 8/44 (18.2%) 4.45 0.45 [0.12, 1.62] 0.35STENTIM-2 3/101 (3.0%) 2/110 (1.8%) 1.14 1.65 [0.27, 10.1] 0.58
STOPAMI-3 25/305 (8.2%) 28/306 (9.2%) 15.71 0.89 [0.50, 1.56] 0.67STOPAMI-4 7/90 (7.8%) 11/91 (12.1%) 6.21 0.61 [0.23, 1.66] 0.33
ZWOLLE-5 3/112 (2.7%) 4/115 (3.5%) 2.35 0.76 [0.17, 3.49] 1.0ZWOLLE-6 47/785 (6.0%) 45/763 (5.9%) 26.26 1.02 [0.67, 1.55] 0.94
TOTAL (95% CI) 169/3298 (5.1%) 173/3298 (5.2%) 100.00 0.97 [0.78, 1.21] 0.81
STENT BETTERSTENT BETTER BALLOON BETTERBALLOON BETTER
ABCIXIMAB 60/919 (6.5%) 55/925 (5.9%) 31.25 1.10 [0.76, 1.61] 0.6CONTROL 109/2379 (4.6%) 118/2373 (5.0%)
0.1 0.2 0.5 1 2 5 10
68.75 0.92 [0.70, 1.20] 0.5
P value
WITHOUT ABCIXIMAB WITHOUT ABCIXIMAB
WITHWITH ABCIXIMAB ABCIXIMAB
De Luca, Suryapranata et al. JACC 2006De Luca, Suryapranata et al. JACC 2006
12-month MORTALITYMetaMeta--AnalysisAnalysis:: StentingStenting vsvs Balloon Balloon forfor STEMISTEMI (13 (13 RCTRCT’’ss; n=6921); n=6921)
IsalaIsala kliniekenklinieken
Underlying Risk Profile
Log (OR) for 12-month Mortality
Sten
tBet
ter
| Bal
loon
Bet
ter
.20.16.12.08.040
1.0
0.5
0.0
-0.5
-1.0
-1.5
Beta=Beta=--00.61.61, , P=P=00.034.034
Underlying Risk Profile.10.08.06.04.020
1.5
1.0
0.5
0.0
-0.5
-1.0
-1.5Beta=-0.63, p=0.022
Log (OR) for 30-day Mortality
Sten
tBet
ter
| Bal
loon
Bet
ter
MetaMeta--RegressionRegression AnalysisAnalysis:: StentingStenting vsvs Balloon Balloon forfor AMI AMI (n=6921)(n=6921)
The higher the risk profile, the greater the benefits from The higher the risk profile, the greater the benefits from StentingStentingDe Luca, Suryapranata et al. JACC 2006De Luca, Suryapranata et al. JACC 2006
IsalaIsala kliniekenklinieken
StudyStudy
DiDi LorenzoLorenzo
BASKETBASKET
HaamuHaamu--StentStent
PASSIONPASSIONSESAMISESAMI
STRATEGYSTRATEGY
TYPHOONTYPHOON
TOTALTOTAL (95% CI)(95% CI)
DESDES BMSBMS%% %%
0.80.84.94.93.73.7
5.35.3
1515
9.79.78.18.1
4.64.66.96.95.65.6
4.84.8 11.611.6
7.67.611.711.720.420.413.413.4
OROR (95% CI)(95% CI)
0.10.1 0.20.2 0.50.5 22 55 101011
FavorsFavors DESDES FavorsFavors BMSBMS
DESDES BMSBMS%% %%
2.52.52.12.19.79.7
4.64.6
55
4.94.95.45.4
1.91.988
2.22.2
3.73.7 4.84.8
6.66.65.45.49.19.12.22.2
OROR (95% CI)(95% CI)
0.10.1 0.20.2 0.50.5 22 55 101011
FavorsFavors DESDES FavorsFavors BMSBMS
TVR TVR @@ 66--12 12 MonthsMonths MortalityMortality @@ 66--12 12 MonthsMonths
MetaMeta--AnalysisAnalysis:: DES DES vsvs BMS BMS forfor STEMISTEMI (n=2360)(n=2360)
No No differencedifference in in StentStent ThrombosisThrombosis (1.2 (1.2 vsvs 1.91.9%%)) oror rere--MIMI (2.3 (2.3 vsvs 2.72.7%%))
IsalaIsala kliniekenklinieken
RandomizedRandomized Trial: DES Trial: DES vsvs BMS BMS forfor STEMI STEMI @@ 11--year F/Uyear F/U
TYPHOONTYPHOON
StentStent ThrombosisThrombosis: : 3.43.4 vsvs 3.63.6%%
CYPHER (n=355)BMS (n=357)
0
4
8
12
16
Death
2.2 2.2
%
P=NS
MI TLR MACE
1.1 1.4P=NS
3.7
12.6
P < 0.001
5.9
14.6
P < 0.001
0
5
10
15
20
25
Restenosis TLR MACE
P<0.05 P<0.05 P<0.05
%BMS (n=230)CYPHER (n=230)
SESAMISESAMI
SpauldingSpaulding et al. NEJM 2006et al. NEJM 2006 Menichelli et al. EuroPCR 2006
No No differencedifference in in MortalityMortality oror rere--MI MI @@ 11--year F/Uyear F/U
IsalaIsala kliniekenklinieken
0
10
20
30
P=0.04
P=0.5 P=1 P=0.06
MACEDeath MI TVR
% BMS + AbciximabSES + Tirofiban
STRATEGYSTRATEGYPASSIONPASSION
StentStent ThrombosisThrombosis: : 11%%
0
4
8
12
Death/MI MACE
4.8
6.5
8.7
12.6%
P=NS P=NS
6.27.4
P=NS
TLR
TAXUS (n=309)BMS (n=310)
Laarman et al. NEJM 2006Laarman et al. NEJM 2006 Valgimigli et al. JAMA 2005
RandomizedRandomized Trial: DES Trial: DES vsvs BMS BMS forfor STEMI STEMI @@ 11--year F/Uyear F/U
IsalaIsala kliniekenklinieken
Pittl et al. WCC 2006
DES DES vsvs BMS BMS forfor STEMI STEMI @@ 66--month F/Umonth F/U
The The safetysafety && efficacyefficacy of DES of DES forfor STEMI STEMI remainremain toto bebe establishedestablished
Kernis SJ et al. Am J Cardiol 2005
DESDES
BMSBMS
Survival (%)P=0.0427P=0.0427
monthmonth
PREMIER RegistryBASKET Trial
0
5
10
15
20
Death Re-MI TVR
P=NS P=NS
P=NS
2.1
5.4
2.84.1
4.9
8.1 7.6
16.7
P=0.053
MACE
BMS (n=74)CYPHER (n=76)TAXUS (n=67)
%%
IsalaIsala kliniekenklinieken
TheThe HORIZONSHORIZONS TrialTrial
P.I: P.I: GreggGregg W. W. StoneStone
3400 STEMI patients 3400 STEMI patients at 200 International sitesat 200 International sitesAspirin 324 mg + Aspirin 324 mg + ClopidogrelClopidogrel 300 or 600 mg300 or 600 mg
Clinical F/U at 1, 6, and 12 months, then yearly for 5 yearsClinical F/U at 1, 6, and 12 months, then yearly for 5 yearsAngiographic F/U at 13 months: 1500 Angiographic F/U at 13 months: 1500 stentstent randomized ptsrandomized pts
Primary PCIPrimary PCI
1:11:1
Bare metal stentBare metal stent(n~750)(n~750)
3:13:1TAXUS SR stentTAXUS SR stent(n~2250)(n~2250)
UFH + UFH + RoutineRoutineIIb/IIIaIIb/IIIa inhibitorinhibitor
BivalirudinBivalirudin ++BailBail--outout IIb/IIIaIIb/IIIa
Eligible for Eligible for StentingStenting
IsalaIsala kliniekenkliniekenDES for AMI seems to be feasible and even more effective in reducing TVR Safety issue of DES on SAT, particularly in AMI’s, has yet to be established
TheThe CEZARCEZAR TrialTrialCypher vs Taxus drug-Eluting stent: A Zwolle AMI Randomized trial
Interim Interim AnalysisAnalysis as of August 31, 2006as of August 31, 2006 (n=269)(n=269)
MACE MACE @@ TAXUSTAXUS CYPHERCYPHER3030--day F/Uday F/U (n=134)(n=134) (n=135)(n=135)
DeathDeath 22 33ReRe--MIMI 44 33CABGCABG 11 00SAT/TLRSAT/TLR 44 554%
TAXUSTAXUS CYPHERCYPHERBaselineBaseline (n=134)(n=134) (n=135)(n=135)
AgeAge ((meanmean, , yrsyrs)) 6060 6161MaleMale (%)(%) 7272 7070DiabetesDiabetes (%)(%) 1212 1111PrevPrev MI/PCIMI/PCI (%)(%) 99 66
IsalaIsala kliniekenklinieken
DrugDrug--ElutingEluting StentStent vsvs Bare Bare MetalMetal StentStentLate Late ThromboticThrombotic EventsEvents @@ 11--yr yr afterafter ClopidogrelClopidogrel DiscontinuationDiscontinuation
DES issue on Late Thrombosis: Due to Impaired Re-endothelialization?Spertus et al. Circulation 2006PfistererPfisterer et al. JACC 2006et al. JACC 2006
BASKET LATE
0
2
4
6
8
10
Death and/or MI
Thrombosis Events
TVR
P=0.01
1.3
4.9
1.3
2.6
6.7
4.5
7.9
9.3
MACE
BMS (n=244)DES (n=499)%% %
P<0.001
MortalityMortality @@ 11--yearyear
PREMIER Registry
ClopidogrelDiscontinuation
Continuation
IsalaIsala kliniekenklinieken
GENOUS GENOUS Endothelial Progenitor CellsEndothelial Progenitor Cells Capture TechnologyCapture Technology
BMS:BMS: Typical neo-intimal response to stent injury
GenousGenous:: Complete healing with mature neo-intima
BrachytherapyBrachytherapy
DrugDrug--Eluting StentEluting Stent
VirmaniVirmani et. al. et. al. HerzHerz 20022002M. M. KutrykKutryk, MD, PhD, St Michael, MD, PhD, St Michael’’s Hospital, Toronto, Canadas Hospital, Toronto, Canada
EEPPCsCs are bone marrow derived, present in the circulating blood, are bone marrow derived, present in the circulating blood, (First described by (First described by AsaharaAsahara in 1996)in 1996)They have the ability to differentiate into mature endothelial cThey have the ability to differentiate into mature endothelial cells, ells, which may which may accelerate Healing process, protect against thrombus, accelerate Healing process, protect against thrombus, and minimize and minimize restenosisrestenosis, with safety profile over current , with safety profile over current DESDES
IsalaIsala kliniekenklinieken
ZwolleZwolle HEALINGHEALING--AMIAMI StudyStudyA pilot trial on safety A pilot trial on safety && feasibility of feasibility of GenousGenous RR--StentStent for AMI for AMI PrePre--treated with treated with statinstatin, aspirin, , aspirin, andand clopidogrelclopidogrel (for only 30(for only 30--d)d)
ClinicalClinical OutcomeOutcome @@ 3030--dd
CardiacCardiac DeathDeath 11ReRe--MIMI 11**SAT + ReSAT + Re--PCIPCI 11**CABGCABG 33**MACEMACE 44
Baseline Baseline CharacteristicsCharacteristics
AgeAge ((yrsyrs)) 5757 (35(35--81)81)MaleMale 3737 7474%%DiabetesDiabetes 77 1414%%HypercholHyperchol 1313 2626%%HypertensionHypertension 1717 3434%%
As of March 31, 2007 (n=50)
PreliminaryPreliminary ResultsResults
** Same patient due to edge dissectionsSame patient due to edge dissections
IsalaIsala kliniekenklinieken
•• Routine Routine stentingstenting in in unselectedunselected STEMISTEMI pts does not seem pts does not seem to improve clinical outcome, when compared to balloonto improve clinical outcome, when compared to balloon
•• StentingStenting has never been shown to reduce mortality rate, has never been shown to reduce mortality rate, but it is only associated with a reduction in TVR/TLRbut it is only associated with a reduction in TVR/TLR
•• Although DES for AMI seems to be feasible Although DES for AMI seems to be feasible && effective effective in reducing TVR, safety issue remains to be establishedin reducing TVR, safety issue remains to be established
•• The potential role of The potential role of GenousGenous stentstent for for STEMISTEMI, to further , to further reduce SAT and ISR, is currently being investigatedreduce SAT and ISR, is currently being investigated
CONCLUSIONCONCLUSION
AMI AMI InterventionIntervention in DES Erain DES Era
IsalaIsala kliniekenkliniekenDedicatedDedicated PCI centers PCI centers withwith adequate adequate netnet--workingworking and expertiseand expertise
Reperfusion Therapy for STEMI in the Real World Reperfusion Therapy for STEMI in the Real World How to Extend the Benefits of Early PCI?How to Extend the Benefits of Early PCI?
√√ ReductionReduction in in totaltotal IschemicIschemic Time: Time: PrePre--hospitalhospital triagetriage(home/ambulance)(home/ambulance) forfor earlyearly identificationidentification of a of a largelarge MIMI
√√ ImmediateImmediate transfer of transfer of allall highhigh--riskrisk ptspts forfor primaryprimary PCIPCI
√√ ImproveImprove regionalregional logisticslogistics
√√ FastFast tracktrack in PCI centersin PCI centers
√√ ““The The EarlyEarly The The BetterBetter””““The The HigherHigher The Risk,The Risk,The The GreaterGreater The BenefitThe Benefit””
Cath labCath labPCI centerPCI center
NonNon--PCI PCI clinicclinic
AmbulanceAmbulance
ER/CCUER/CCU
IsalaIsala kliniekenklinieken
The Golden The Golden HourHour in in CasualtiesCasualties of Warof War
Dominique-Jean Larrey1766 - 1842
1797 Italian Campaign:- Heaviest wounded First- Treatment < 15 minutes- On the spot at front line MASHMASH
(Mobile (Mobile ArmyArmy SurgicalSurgical HospitalHospital))Korea 1951Korea 1951--19531953
Lt. R. Adams Lt. R. Adams CowleyCowley